ImmunoPET: concept, design, and applications

W Wei, ZT Rosenkrans, J Liu, G Huang, QY Luo… - Chemical …, 2020 - ACS Publications
Immuno-positron emission tomography (immunoPET) is a paradigm-shifting molecular
imaging modality combining the superior targeting specificity of monoclonal antibody (mAb) …

Multifaceted role of the urokinase-type plasminogen activator (uPA) and its receptor (uPAR): diagnostic, prognostic, and therapeutic applications

N Mahmood, C Mihalcioiu, SA Rabbani - Frontiers in oncology, 2018 - frontiersin.org
The plasminogen activator (PA) system is an extracellular proteolytic enzyme system
associated with various physiological and pathophysiological processes. A large body of …

Peptide-based agents for cancer treatment: current applications and future directions

NTT Nhàn, T Yamada, KH Yamada - International Journal of Molecular …, 2023 - mdpi.com
Peptide-based strategies have received an enormous amount of attention because of their
specificity and applicability. Their specificity and tumor-targeting ability are applied to …

Therapeutics targeting the fibrinolytic system

H Lin, L Xu, S Yu, W Hong, M Huang… - Experimental & molecular …, 2020 - nature.com
The function of the fibrinolytic system was first identified to dissolve fibrin to maintain
vascular patency. Connections between the fibrinolytic system and many other physiological …

Modulation of cellular function by the urokinase receptor signalling: A mechanistic view

D Alfano, P Franco, MP Stoppelli - Frontiers in Cell and …, 2022 - frontiersin.org
Urokinase-type plasminogen activator receptor (uPAR or CD87) is a glycosyl-phosphatidyl-
inositol anchored (GPI) membrane protein. The uPAR primary ligand is the serine protease …

Selecting targets for tumor imaging: an overview of cancer-associated membrane proteins

MC Boonstra, SWL De Geus… - Biomarkers in …, 2016 - journals.sagepub.com
Tumor targeting is a booming business: The global therapeutic monoclonal antibody market
accounted for more than $78 billion in 2012 and is expanding exponentially. Tumors can be …

Therapeutic strategies targeting urokinase and its receptor in cancer

MT Masucci, M Minopoli, G Di Carluccio, ML Motti… - Cancers, 2022 - mdpi.com
Simple Summary The uPA/uPAR system is highly involved in cancer progression and
metastasis. Many studies have definitively assessed that the high expression of urokinase …

[HTML][HTML] uPAR: an essential factor for tumor development

T Lv, Y Zhao, X Jiang, H Yuan, H Wang, X Cui… - Journal of …, 2021 - ncbi.nlm.nih.gov
Tumorigenesis is closely related to the loss of control of many genes. Urokinase-type
plasminogen activator receptor (uPAR), a glycolipid-anchored protein on the cell surface, is …

The emerging role of copper-64 radiopharmaceuticals as cancer theranostics

A Boschi, P Martini, E Janevik-Ivanovska, A Duatti - Drug Discovery Today, 2018 - Elsevier
Highlights•Copper radionuclides for in vivo imaging of biological functions of copper
ions.•Copper-64 has suitable nuclear properties for cancer theranostics.•Radioactive copper …

The urokinase receptor (uPAR) as a “Trojan Horse” in targeted cancer therapy: challenges and opportunities

V Metrangolo, M Ploug, LH Engelholm - Cancers, 2021 - mdpi.com
Simple Summary Discovered more than three decades ago, the urokinase-type
plasminogen activator receptor (uPAR) has now firmly established itself as a versatile …